The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non-Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review

被引:3
作者
Schwartz, Candice [1 ]
Pfanzelter, Nicklas [2 ]
Kuzel, Timothy M. [2 ]
机构
[1] Rush Univ, Med Ctr, Dept Internal Med, Chicago, IL 60612 USA
[2] Rush Univ, Med Ctr, Dept Internal Med, Div Hematol Oncol Cell Therapy, Chicago, IL 60612 USA
关键词
Chromophobe; Everolimus; Lenvatinib; Noneclear-cell renal cell carcinoma; Treatment; OPEN-LABEL; SUNITINIB; MULTICENTER; PHASE-2;
D O I
10.1016/j.clgc.2017.05.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
First- and second-line treatments for metastatic none clear-cell renal cell carcinoma (nccRCC) are not extensively studied and based on the well-defined treatments for metastatic clear cell renal cell carcinoma (ccRCC). Lenvatinib and everolimus have been studied in patients with ccRCC and are now established second-line therapy. This case report describes the use of lenvatinib and everolimus in a patient with metastatic nccRCC, and resultant marked reduction in tumor burden. Although it has been studied in patients with ccRCC, additional trials evaluating lenvatinib and everolimus may confirm the efficacy of this treatment regimen in patients with nccRCC.
引用
收藏
页码:E903 / E906
页数:4
相关论文
共 50 条
[31]   Systemic therapy for non-clear cell renal cell carcinomas: A systematic review [J].
Ara, Balqees ;
Babar, Anum ;
Atif, Durkho ;
Ghafoor, Bushra ;
Shah, Mustafa ;
Abdullah, Syed Maaz ;
Safi, Danish ;
Kamran, Amir .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2025, 31 (01) :128-140
[32]   The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma [J].
Jacob, Allen ;
Shook, Jaret ;
Hutson, Thomas .
EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (04) :365-372
[33]   Systematic Review of Treatment of Metastatic Non-Clear Cell Renal Cell Carcinoma [J].
Brown, Jason R. ;
Calaway, Adam ;
Castle, Erik ;
Garcia, Jorge ;
Barata, Pedro C. .
KIDNEY CANCER, 2022, 6 (01) :53-68
[34]   Paraneoplastic digital ischemia in clear-cell renal-cell carcinoma: Report of a case and review of the literature [J].
Kampoli, Katerina ;
Gardeli, Dimitra ;
Mouktaroudi, Maria ;
Fanouriakis, Antonis ;
Lazaris, Andreas M. ;
Koumarianou, Anna .
UROLOGIA JOURNAL, 2019, 86 (03) :156-160
[35]   The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review [J].
Sneed, Gregory T. ;
Lee, Sukdong ;
Brown, Jamie N. ;
Hammond, Julia M. .
CLINICAL GENITOURINARY CANCER, 2019, 17 (06) :419-424
[36]   Chromophobe renal cell carcinoma with sarcomatoid and heterologous osteosarcoma-like differentiation: a case report and literature review [J].
Abuorouq, Saleh ;
Sahawneh, Firas ;
Halalsheh, Omar ;
Haddad, Husam K. ;
Mekail, Raed ;
Alzoubi, Hiba ;
Alrjoub, Mo'ath ;
Serhan, Hashem A. .
JOURNAL OF SURGICAL CASE REPORTS, 2023, 2023 (08)
[37]   Chromophobe variant of renal cell carcinoma - A rare case report [J].
Bhalsod, Harsh Dinesh ;
Khan, Imran Ali .
MEDICAL SCIENCE, 2021, 25 (110) :812-815
[38]   Systemic Therapy for Metastatic Non-Clear-Cell Renal Cell Carcinoma: Recent Progress and Future Directions [J].
Chowdhury, Simon ;
Matrana, Marc R. ;
Tsang, Christopher ;
Atkinson, Bradley ;
Choueiri, Toni K. ;
Tannir, Nizar M. .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 25 (04) :853-+
[39]   Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61) a single-arm, multicentre, phase 2 trial  [J].
Albiges, Laurence ;
Gurney, Howard ;
Atduev, Vagif ;
Suarez, Cristina ;
Climent, Miguel A. ;
Pook, David ;
Tomczak, Piotr ;
Barthelemy, Philippe ;
Lee, Jae Lyun ;
Stus, Viktor ;
Ferguson, Thomas ;
Wiechno, Pawel ;
Gokmen, Erhan ;
Lacombe, Louis ;
Gedye, Craig ;
Perini, Rodolfo F. ;
Sharma, Manish ;
Peng, Xiang ;
Lee, Chung-Han .
LANCET ONCOLOGY, 2023, 24 (08) :881-891
[40]   Retro-orbital Metastasis in Chromophobe Renal Cell Carcinoma: A Case Report and Review [J].
Kapagan, Tanju ;
Bulut, Nilufer ;
Halici, Mehmet ;
Erdem, Gokmen Umut .
ARCHIVES OF IRANIAN MEDICINE, 2025, 28 (03) :171-173